Abstract | PURPOSE: METHODS: One eye each of 32 patients who were treated with intravitreal injections for macular edema secondary to BRVO was studied. This retrospective study included 3 groups. The patients received DEX in group 1 (n = 11), RAN in group 2 (n = 11), and IVTA in group 3 (n = 10). Data were collected before and after the injections at the first and third months. Best-corrected visual acuity (BCVA), central macular thickness (CMT), and intraocular pressure (IOP) were analyzed statistically. RESULTS: The median duration of the follow-up was 3.0 months in overall groups. The BCVA increased significantly in all groups (p = 0.018, p = 0.034, p = 0.014, respectively). The CMT increased significantly in groups 1 and 3 (p = 0.02, p<0.001, respectively), but not in group 2 (p = 0.14). The IOP increased significantly in groups 1 and 3 (p = 0.05, p<0.001, respectively). Antiglaucomatous treatment was required only in group 3. Cataract developed in 2 patients (20%) in group 3 and surgery was required. CONCLUSIONS: Although RAN was the safest among the 3 agents, DEX and IVTA reduced CMT more than RAN, while significant improvement was achieved in BCVA in all groups. All 3 agents can be effectively used in the treatment of macular edema due to BRVO.
|
Authors | Erhan Yumusak, Nesrin Buyuktortop, Kemal Ornek |
Journal | European journal of ophthalmology
(Eur J Ophthalmol)
2016 Jan-Feb
Vol. 26
Issue 1
Pg. 54-9
ISSN: 1724-6016 [Electronic] United States |
PMID | 26109021
(Publication Type: Comparative Study, Journal Article)
|
Chemical References |
- Angiogenesis Inhibitors
- Drug Implants
- Glucocorticoids
- VEGFA protein, human
- Vascular Endothelial Growth Factor A
- Dexamethasone
- Triamcinolone Acetonide
- Ranibizumab
|
Topics |
- Aged
- Aged, 80 and over
- Angiogenesis Inhibitors
(therapeutic use)
- Dexamethasone
(administration & dosage)
- Drug Implants
- Female
- Glucocorticoids
(administration & dosage)
- Humans
- Intraocular Pressure
(drug effects, physiology)
- Intravitreal Injections
- Macula Lutea
(pathology)
- Macular Edema
(drug therapy, etiology)
- Male
- Middle Aged
- Organ Size
- Ranibizumab
(therapeutic use)
- Retinal Vein Occlusion
(complications, drug therapy)
- Retrospective Studies
- Tonometry, Ocular
- Treatment Outcome
- Triamcinolone Acetonide
(administration & dosage)
- Vascular Endothelial Growth Factor A
(antagonists & inhibitors)
- Visual Acuity
(drug effects, physiology)
|